EXOZ
Price
$4.56
Change
+$0.01 (+0.22%)
Updated
Oct 14 closing price
Capitalization
55.69M
Intraday BUY SELL Signals
ORIC
Price
$11.59
Change
+$0.28 (+2.48%)
Updated
Oct 14 closing price
Capitalization
1.38B
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EXOZ vs ORIC

EXOZ vs ORIC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EXOZ vs. ORIC commentary
Oct 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXOZ is a Hold and ORIC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EXOZ with price predictions
Oct 14, 2026

Momentum Indicator for EXOZ turns negative, indicating new downward trend

EXOZ saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator turned negative. In 28 of the 29 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

EXOZ moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EXOZ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXOZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for EXOZ entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXOZ advanced for three days, in 76 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

EXOZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.267) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. EXOZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXOZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ORIC with price predictions
Oct 14, 2026

ORIC in downward trend: 10-day moving average crossed below 50-day moving average on October 06, 2026

The 10-day moving average for ORIC crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORIC as a result. In 63 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ORIC turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

ORIC moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ORIC broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ORIC entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORIC's RSI Indicator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +0.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORIC advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.608) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ORIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ORIC: Fundamental Ratings
ORIC
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EXOZORIC
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 21 days ago
90%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 15, 2026
Stock price -- (EXOZ: $4.56 vs. ORIC: $11.59)
Brand notoriety: EXOZ and ORIC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXOZ: 124% vs. ORIC: 126%
Market capitalization -- EXOZ: $55.69M vs. ORIC: $1.38B
EXOZ [@Biotechnology] is valued at $55.69M. ORIC’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXOZ’s FA Score shows that 0 FA rating(s) are green while ORIC’s FA Score has 1 green FA rating(s).

  • EXOZ’s FA Score: 0 green, 5 red.
  • ORIC’s FA Score: 1 green, 4 red.
According to our system of comparison, ORIC is a better buy in the long-term than EXOZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXOZ’s TA Score shows that 4 TA indicator(s) are bullish while ORIC’s TA Score has 3 bullish TA indicator(s).

  • EXOZ’s TA Score: 4 bullish, 5 bearish.
  • ORIC’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, EXOZ is a better buy in the short-term than ORIC.

Price Growth

EXOZ (@Biotechnology) experienced а -17.39% price change this week, while ORIC (@Biotechnology) price change was -3.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.

Reported Earning Dates

ORIC is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-8.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EXOZ
Daily Signal:
Gain/Loss:
ORIC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FXH131.601.71
+1.32%
First Trust Health Care AlphaDEX Fund (FXH)
PSL112.811.20
+1.08%
Invesco Dorsey Wright Consumer Staples Momentum ETF (PSL)
CVSB50.51-0.01
-0.02%
Calvert Ultra-Short Investment Grade ETF (CVSB)
MFLX15.97-0.01
-0.09%
First Trust Flexible Municipal High Income ETF (MFLX)
MSML70.46-1.06
-1.48%
iShares MSCI USA Small-Cap ETF (MSML)

EXOZ and

Correlation & Price change

A.I.dvisor tells us that EXOZ and CTNM have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXOZ and CTNM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXOZ
1D Price
Change %
EXOZ100%
+0.22%
CTNM - EXOZ
24%
Poorly correlated
-3.33%
EDVA - EXOZ
21%
Poorly correlated
-0.92%
ORIC - EXOZ
21%
Poorly correlated
+2.48%
MENS - EXOZ
11%
Poorly correlated
+0.49%
LIMN - EXOZ
9%
Poorly correlated
-4.69%
More

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with REPL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
+2.48%
REPL - ORIC
37%
Loosely correlated
-5.95%
RKTO - ORIC
37%
Loosely correlated
-6.73%
WVE - ORIC
36%
Loosely correlated
-1.59%
TRVI - ORIC
35%
Loosely correlated
-1.87%
RCUS - ORIC
35%
Loosely correlated
+0.09%
More